Literature DB >> 1883540

Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys.

M Murphey-Corb1, R C Montelaro, M A Miller, M West, L N Martin, B Davison-Fairburn, S Ohkawa, G B Baskin, J Y Zhang, G B Miller.   

Abstract

Immunization with an inactivated whole-virus vaccine is highly effective in preventing lentivirus infection. The viral protein(s) essential to the induction of protective responses, however, have not been identified. To define the role of virion components in the induction of protective immunity, we evaluated the efficacy of glycoprotein-enriched and glycoprotein-depleted simian immunodeficiency virus (SIV) subunit vaccines prepared by lentil-lectin affinity chromatography of gradient-purified virions using the immunization and challenge regimen previously found successful with an inactivated whole-virus vaccine. Infection was determined by successful recovery of virus, the induction of SIV-specific antibody responses, and infection of naive recipients by inoculation with lymph-node-derived lymphocytes from the vaccinates. Immunization with the glycoprotein-enriched preparation prevented infection in two out of four monkeys, whereas the glycoprotein-depleted vaccine failed to prevent infection in all four vaccinates tested. However, the glycoprotein-depleted vaccine appeared to moderate the progression of SIV-induced disease compared with non-immunized infected control monkeys inoculated with the same challenge dose. These data suggest that subunit vaccines containing sufficient quantities of viral glycoproteins can protect against SIV infection, whereas subunit vaccines composed predominantly of viral core proteins cannot. The development of effective vaccines against HIV infection should include studies on the optimum presentation of the viral envelope glycoproteins to produce long-term broadly protective immune responses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1883540     DOI: 10.1097/00002030-199106000-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

1.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

2.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Authors:  K S Cole; J L Rowles; B A Jagerski; M Murphey-Corb; T Unangst; J E Clements; J Robinson; M S Wyand; R C Desrosiers; R C Montelaro
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

3.  Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5).

Authors:  E G Hulskotte; A M Geretti; K H Siebelink; G van Amerongen; M P Cranage; E W Rud; S G Norley; P de Vries; A D Osterhaus
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

4.  Gene inoculation generates immune responses against human immunodeficiency virus type 1.

Authors:  B Wang; K E Ugen; V Srikantan; M G Agadjanyan; K Dang; Y Refaeli; A I Sato; J Boyer; W V Williams; D B Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

5.  Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines.

Authors:  Z R Israel; P F Edmonson; D H Maul; S P O'Neil; S P Mossman; C Thiriart; L Fabry; O Van Opstal; C Bruck; F Bex
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 6.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

7.  Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

Authors:  S P Mossman; F Bex; P Berglund; J Arthos; S P O'Neil; D Riley; D H Maul; C Bruck; P Momin; A Burny; P N Fultz; J I Mullins; P Liljeström; E A Hoover
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

8.  Replication and persistence of simian immunodeficiency virus variants after passage in macaque lymphocytes and established human cell lines.

Authors:  L M Rudensey; M D Papenhausen; J Overbaugh
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

9.  Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.

Authors:  L D Giavedoni; V Planelles; N L Haigwood; S Ahmad; J D Kluge; M L Marthas; M B Gardner; P A Luciw; T D Yilma
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

10.  Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.

Authors:  C J Issel; D W Horohov; D F Lea; W V Adams; S D Hagius; J M McManus; A C Allison; R C Montelaro
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.